What’s new in molecular genetic pathology 2022: Immune checkpoint inhibitor biomarkers and select solid tumors

Patricia C. Tsang; Guoli Chen

doi:10.4132/jptm.2022.01.25

What’s new in molecular genetic pathology 2022: Immune checkpoint inhibitor biomarkers and select solid tumors

Patricia C. Tsang, Guoli Chen

Department of Pathology and Laboratory Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.

Original language	English (US)
Pages (from-to)	113-114
Number of pages	2
Journal	Journal of Pathology and Translational Medicine
Volume	56
Issue number	2
DOIs	https://doi.org/10.4132/jptm.2022.01.25
State	Published - 2022

All Science Journal Classification (ASJC) codes

Pathology and Forensic Medicine
Histology

Access to Document

10.4132/jptm.2022.01.25

Cite this

@article{a45d6fc9f330485bb9a152823751c737,

title = "What{\textquoteright}s new in molecular genetic pathology 2022: Immune checkpoint inhibitor biomarkers and select solid tumors",

abstract = "Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.",

author = "Tsang, {Patricia C.} and Guoli Chen",

note = "Publisher Copyright: {\textcopyright} 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology",

year = "2022",

doi = "10.4132/jptm.2022.01.25",

language = "English (US)",

volume = "56",

pages = "113--114",

journal = "Journal of Pathology and Translational Medicine",

issn = "2383-7837",

publisher = "Korean Society of Pathologists",

number = "2",

}

TY - JOUR

T1 - What’s new in molecular genetic pathology 2022

T2 - Immune checkpoint inhibitor biomarkers and select solid tumors

AU - Tsang, Patricia C.

AU - Chen, Guoli

PY - 2022

Y1 - 2022

N2 - Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.

AB - Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.

UR - http://www.scopus.com/inward/record.url?scp=85131238612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131238612&partnerID=8YFLogxK

U2 - 10.4132/jptm.2022.01.25

DO - 10.4132/jptm.2022.01.25

M3 - Article

C2 - 35306778

AN - SCOPUS:85131238612

SN - 2383-7837

VL - 56

SP - 113

EP - 114

JO - Journal of Pathology and Translational Medicine

JF - Journal of Pathology and Translational Medicine

IS - 2

ER -

What’s new in molecular genetic pathology 2022: Immune checkpoint inhibitor biomarkers and select solid tumors

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this